Sign in
Not yet recruitingNo phase

Integrated Multi-Omics Analysis of Treatment-Naive Patients With Chronic HBV Infection

Key facts

Who runs it
Beijing Municipal Administration of Hospitals
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
1,000 people, planned
Started
1 Nov 2026
Expected to end
1 Oct 2028
Type of study
Observational
Record updated
13 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (13)Hide the full registry criteria

Who can take part

  • Persistent hepatitis B surface antigen (HBsAg) positivity for more than 6 months
  • Diagnosis of chronic hepatitis B virus (HBV) infection
  • No previous treatment with nucleos(t)ide analogues or interferon before the study observation time point
  • No previous use of immunomodulatory agents or hepatoprotective and anti-inflammatory medications that may significantly affect the study-related indicators before the observation time point
  • Availability of demographic, clinical biochemical, and virological data required for the study
  • Availability of stored serum samples that can be accurately matched with clinical data and meet the quality requirements for subsequent analyses
  • For existing cases, reuse of clinical data and samples must comply with the ethics committee's approval and applicable informed consent requirements. Prospectively enrolled participants must provide written informed consent

Who cannot take part

  • Concurrent autoimmune liver disease
  • Coinfection with other viral hepatitis infections, including hepatitis A, C, or E
  • Alcohol-associated liver disease
  • Incomplete clinical records, virological data, or stored serum samples that do not meet the requirements for the planned analyses
  • Advanced liver cirrhosis
  • Hepatocellular carcinoma

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Hepatitis B

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a single-center, cross-sectional, observational study involving approximately 1,000 treatment-naive patients with chronic hepatitis B virus (HBV) infection at Beijing Ditan Hospital, Capital Medical University.

Read full original descriptionShow less

The study aims to investigate the relationship between HBV genetic characteristics, host molecular profiles, and clinical features of chronic HBV infection. Clinical and laboratory information, including liver function tests, HBV DNA levels, hepatitis B surface antigen (HBsAg) levels, and liver fibrosis assessments, will be collected from eligible participants.

Existing clinical data and stored serum samples will be used when authorized and approved by the Ethics Committee. Newly enrolled participants will contribute residual serum samples obtained after routine clinical testing. No additional blood collection or experimental treatment will be required for this study.

HBV whole-genome sequencing data will be analyzed to characterize viral genotypes, mutations, and viral diversity. In approximately 300 selected participants, serum metabolomics, quantitative proteomics, and immune-related factors will also be examined.

By integrating viral, metabolic, protein, immune, and clinical data, this study aims to identify molecular features and potential biomarkers associated with liver inflammation, early liver fibrosis, viral replication, and HBsAg expression. The findings may help improve understanding of differences among patients with chronic HBV infection and provide a basis for future research on risk assessment and disease management.

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Cross-Sectional Integrated Multi-Omics Study of Treatment-Naive Patients With Chronic Hepatitis B Virus Infection
Criteria questions
Built from NCT07935148, who can take part
Record updated
13 November 2026